Necroptosis-Mediated eCIRP Release in Sepsis

Area of Science:

• Immunology
• Cell Biology
• Molecular Medicine

Background:

• Extracellular cold-inducible RNA-binding protein (eCIRP) is a pro-inflammatory mediator implicated in sepsis.
• The precise mechanisms governing eCIRP release remain incompletely understood.
• Necroptosis, a regulated form of cell death, involves mixed lineage kinase domain-like pseudo kinase (MLKL) activation and the release of damage-associated molecular patterns.

Purpose of the Study:

• To investigate the role of necroptosis in the release of eCIRP during sepsis.
• To determine if targeting necroptosis can mitigate inflammation and injury in sepsis.

Main Methods:

• Utilized RAW264.7 cells treated with LPS and necroptosis inhibitors (z-VAD, Necrostatin-1).
• Assessed eCIRP release and MLKL phosphorylation (p-MLKL) via Western blot and LDH assay.
• Induced sepsis in mice using cecal ligation and puncture (CLP) and treated with Necrostatin-1.
• Measured serum and peritoneal fluid levels of eCIRP, TNF-α, and IL-6 using ELISA.

Main Results:

• LPS+z-VAD treatment induced necroptosis and eCIRP release in cell cultures.
• Necrostatin-1 inhibited p-MLKL activation and eCIRP release in vitro.
• Necrostatin-1 treatment reduced eCIRP, TNF-α, and IL-6 levels in septic mice.
• Computational modeling suggested eCIRP release through MLKL pores.

Conclusions:

• Necroptosis represents a novel pathway for eCIRP release in sepsis.
• Inhibition of necroptosis may serve as a therapeutic strategy to reduce inflammation and injury in sepsis by blocking eCIRP release.